Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion

This article was originally published in The Gray Sheet

Executive Summary

Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.

Related Content

Stryker M&A Strategy Intact Under New CEO With Latest Deal For Stroke Care
Intracranial Stenting Doesn’t Make The Cut In NIH Study
Stryker Buys Concentric Medical To Enter Acute Ischemic Stroke Market
People In Brief
After J&J-Synthes Deal, Will Orthopedic Consolidation Hit Zimmer, Stryker?
Investing In Ortho Pipeline Could Offset Pricing Pressures – Stryker, Zimmer
Boston Scientific Buys Atritech For Watchman Stroke Prevention Device
Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
Boston Sci Makes Its Play In Transcatheter Valves With Sadra Acquisition
Boston Scientific shops neuro businesses





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts